|
1. BIOLOGIE
|
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
A marriage of microscopy and machine learning [Broad Institute]
|
|
|
|
|
|
This approach, called “Cell Painting,” uses six biological dyes to stain eight major cell structures. Together, they create not just beautiful images, but also a detailed portrait of the cells’ size, shape or morphology, and—if you can read the signs—physiological state.
|
|
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
FDA and NIH let clinical trial sponsors keep results secret and break the law [Science]
|
|
|
|
|
|
The violations cover trials in virtually all fields of medicine, and the missing or late results offer potentially vital information for the most desperate patients. For example, in one long-overdue trial, researchers compared the efficacy of different chemotherapy regimens in 200 patients with advanced lymphoma; another—nearly 2 years late—tests immunotherapy against conventional chemotherapy in about 600 people with late-stage lung cancer.
|
|
|
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug [Xconomy]
|
|
|
|
|
|
Tafasitamab is an antibody drug designed to target CD19, a protein broadly expressed in various B cell lymphomas. MorphoSys says its drug binds to this protein, which in turn attracts an immune response from natural killer cells and macrophages. Those immune cells attach themselves to the cancer cells and kill them.
|
|
|
|
|
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
Eli Lilly ditches NextCure pact [Fierce Biotech]
|
|
|
|
|
|
That deal, which also included undisclosed milestones, was built upon a platform for scouring cell surface interactions in search of targets that affect immune function with NextCure, which is staffed by executives who led Amplimmune to a takeover by AstraZeneca.
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
Big Pharma partner Schrödinger wants a $100M IPO [Fierce Biotech]
|
|
|
|
|
|
To date, Schrödinger has shared few details of the specifics of its internal activities, reflecting their early-stage nature. But its track record of playing a role in two Agios cancer drugs that won approval and the several undisclosed assets in the clinic demonstrate its credentials.
|
|
|
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
The global challenge of cancer [Nature Cancer]
|
|
|
|
|
|
Cancer is a multifaceted global health issue that continues to demand action. We are launching Nature Cancer to inform, inspire and convene scientists across the multidisciplinary arena of cancer research, aiming to advance biomedical knowledge and treatment strategies within the greater framework of society.
|
|
|
|
|
|
|
A roadmap for the next decade in cancer research [Nature Cancer]
|
|
|
|
|
|
Cancer research in recent years has been marked by significant developments in understanding disease biology and foundational discoveries that have changed clinical practice. Ten cancer researchers take stock of the field, the advances that excite them, key outstanding questions and breakthroughs they anticipate looking forward.
|
|
|
|
|
|
|
Shaping the future of cancer research at NCI [Nature Cancer]
|
|
|
|
|
|
Norman E. ‘Ned’ Sharpless became director of the US National Cancer Institute (NCI) in 2017. From April 2019, he served as acting commissioner of the US Food and Drug Administration (FDA), and he returned to the NCI in November. Douglas R. Lowy has been the principal deputy director of the NCI since 2010, having also served as acting director twice, most recently in 2019.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
Axes of a revolution: challenges and promises of big data in healthcare [Nature Medicine]
|
|
|
|
|
|
Analysis of big data in health has many challenges and is in some sense a double-edged sword. On one hand, it provides a much wider perspective on states of health and disease, but on the other hand, it provides the temptation to delve into the details of molecular descriptions that may miss the big picture (as in the ‘seeing the whole elephant’ analogy).
|
|
|
|
|
|
|
|
6.7.3 DMP
|
|
|